WO1999055663A1 - Inhibiteurs de l'enzyme impdh - Google Patents

Inhibiteurs de l'enzyme impdh Download PDF

Info

Publication number
WO1999055663A1
WO1999055663A1 PCT/US1999/009005 US9909005W WO9955663A1 WO 1999055663 A1 WO1999055663 A1 WO 1999055663A1 US 9909005 W US9909005 W US 9909005W WO 9955663 A1 WO9955663 A1 WO 9955663A1
Authority
WO
WIPO (PCT)
Prior art keywords
straight
branched alkyl
alkyl
branched
alkynyl
Prior art date
Application number
PCT/US1999/009005
Other languages
English (en)
Inventor
Jeffrey Saunders
Daniel Elbaum
Perry Novak
Douglas Naegele
Scott Bethiel
Steven Ronkin
Michael Badia
Catharine Frank
Dean Stamos
William Walters
David Pearlman
Original Assignee
Vertex Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated
Priority to EP99918831A priority Critical patent/EP1076641A1/fr
Priority to JP2000545824A priority patent/JP2002512997A/ja
Priority to AU36651/99A priority patent/AU3665199A/en
Publication of WO1999055663A1 publication Critical patent/WO1999055663A1/fr
Priority to US09/702,991 priority patent/US6653309B1/en
Priority to US10/671,967 priority patent/US7989498B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
    • C07C217/84—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/75—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/66—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems and singly-bound oxygen atoms, bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/88—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having the nitrogen atom of at least one of the carboxamide groups further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/48—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring being part of a condensed ring system of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to compounds which inhibit IMPDH.
  • This invention also relates to pharmaceutical compositions comprising these compounds.
  • the compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting IMPDH enzyme activity and consequently, may be advantageously used as therapeutic agents for IMPDH mediated processes.
  • This invention also relates to methods for inhibiting the activity of IMPDH using the compounds of this invention and related compounds.
  • nucleotide synthesis in organisms is required for the cells in those organisms to divide and replicate. Nucleotide synthesis in mammals may be achieved through one of two pathways : the de novo synthesis pathway or the salvage pathway. Different cell types use these pathways to a different extent.
  • Inosine-5 ' -monophosphate dehydrogenase (IMPDH; EC 1.1.1.205) is an enzyme involved in the de novo synthesis of guanosine nucleotides.
  • IMPDH catalyzes the NAD-dependent oxidation of inosine-5 ' -monophosphate (IMP) to xanthosine-5 ' -monophosphate (XMP) [Jackson R.C. et. al., Nature, 256, pp. 331-333, (1975)].
  • IMPDH inosine-5 ' -monophosphate
  • XMP xanthosine-5 ' -monophosphate
  • IMPDH is ubiquitous in eukaryotes, bacteria and protozoa [Y. Natsumeda & S.F. Carr, Ann. N. Y. Acad. , 696, pp. 88-93 (1993)].
  • the prokaryotic forms share 30-40% sequence identity with the human enzyme. Regardless of species, the enzyme follows an ordered Bi-Bi reaction sequence of substrate and cofactor binding and product release. First, IMP binds to IMPDH. This is followed by the binding of the cofactor NAD. The reduced cofactor, NADH, is then released from the product, followed by the product, XMP [S.F. Carr et al . , J. Biol. Chem., 268, pp. 27286-90 (1993); E.W.
  • guanosine nucleotides and thus the activity of IMPDH, is particularly important in B and T-lymphocytes. These cells depend on the de novo, rather than salvage pathway to generate sufficient levels of nucleotides necessary to initiate a proliferative response to mitogen or antigen [A.C. Allison et. al . , Lancet II, 1179, (1975) and A.C. Allison - 3 -
  • IMPDH is an attractive target for selectively inhibiting the immune system without also inhibiting the proliferation of other cells.
  • Immunosuppression has been achieved by inhibiting a variety of enzymes including for example, the phosphatase calcineurin (inhibited by cyclosporin and FK-506); dihydroorotate dehydrogenase, an enzyme involved in the biosynthesis of pyrimidines (inhibited by leflunomide and brequinar) ; the kinase FRAP (inhibited by rapamycin) ; and the heat shock protein hsp70 (inhibited by deoxyspergualin) .
  • the phosphatase calcineurin inhibited by cyclosporin and FK-506
  • dihydroorotate dehydrogenase an enzyme involved in the biosynthesis of pyrimidines (inhibited by leflunomide and brequinar)
  • the kinase FRAP inhibited by rapamycin
  • Inhibitors of IMPDH are also known.
  • United States patents 5,380,879 and 5,444,072 and PCT publications WO 94/01105 and WO 94/12184 describe mycophenolic acid (MPA) and some of its derivatives as potent, uncompetitive, reversible inhibitors of human
  • MPA has been demonstrated to block the response of B and T-cells to mitogen or antigen [A. C. Allison et. al., Ann . N. Y. Acad. Sci., 696, 63, (1993). Immunosuppressants, such as MPA, are useful drugs in the treatment of transplant rejection and autoimmune diseases. [R. E. Morris, Kidney Intl . , 49, Suppl. 53, S-26, (1996)]. However, MPA is characterized by undesirable pharmacological properties, such as gastrointestinal toxicity and poor bioavailability. [L. M. Shaw, et. al . , Therapeutic Drug Monitoring, 17, pp. 690-699, (1995)]. - 4 -
  • Nucleoside analogs such as tiazofurin, ribavirin and mizoribine also inhibit IMPDH [L. Hedstrom, et. al. Biochemistry, 29, pp. 849-854 (1990)]. These compounds, which are competitive inhibitors of IMPDH, suffer from lack of specificity to this enzyme.
  • Mycophenolate mofetil a prodrug which quickly liberates free MPA in vivo, was recently approved to prevent acute renal allograft rejection following kidney transplantation. [L. M. Shaw, et. al . , Therapeutic Drug Monitoring, 17, pp. 690-699, (1995); H. W. Sollinger, Transplantation, 60, pp. 225-232 (1995)]. Several clinical observations, however, limit the therapeutic potential of this drug. [L. M. Shaw, et. al . , Therapeutic Drug Monitoring, 17, pp. 690-699, (1995)]. MPA is rapidly metabolized to the inactive glucuronide in vivo . [A.C. Allison and E.M. Eugui, Immunological Reviews, 136, pp.
  • IMPDH inhibitors of a different class have been described in PCT publication WO 97/40028. It is also known that IMPDH plays a role in other metabolic events. Increased IMPDH activity has been observed in rapidly proliferating human leukemic cell lines and other tumor cell lines, indicating IMPDH as a target for anti-cancer as well as immunosuppressive chemotherapy [M. Nagai et . al . , Cancer Res . , 51, pp.
  • IMPDH has also been shown to play a role in the proliferation of smooth muscle cells, indicating that inhibitors of IMPDH, such as MPA or rapamycin, may be useful in preventing restenosis or other hyperproliferative vascular diseases [C. R. Gregory et al., Transplantation, 59, pp. 655-61 (1995); PCT publication WO 94/12184; and PCT publication WO 94/01105] .
  • IMPDH has been shown to play a role in viral replication in some viral cell lines. [S.F. Carr, J. Biol. Chem., 268, pp. 27286-27290 (1993)]. Analogous to lymphocyte and tumor cell lines, the implication is that the de novo, rather than the salvage, pathway is critical in the process of viral replication.
  • inhibitors with improved pharmacological properties.
  • Such inhibitors would have therapeutic potential as immunosuppressants, anti-cancer agents, anti-vascular hyperproliferative agents, anti-inflammatory agents, antifungal agents, antipsoriatic and anti-viral agents.
  • the present invention provides compounds, and pharmaceutically acceptable derivatives thereof, that are useful as inhibitors of IMPDH. These compounds can be used alone or in combination with other therapeutic or prophylactic agents, such as anti-virals, anti- inflammatory agents, antibiotics, and immunosuppressants for the treatment or prophylaxis of transplant rejection and autoimmune disease.
  • therapeutic or prophylactic agents such as anti-virals, anti- inflammatory agents, antibiotics, and immunosuppressants for the treatment or prophylaxis of transplant rejection and autoimmune disease.
  • these compounds are useful, alone or in combination with other agents, as therapeutic and prophylactic agents for antiviral, anti-tumor, anti- cancer, anti-inflammatory agents, antifungal agents, 6 -
  • the invention also provides pharmaceutical compositions comprising the compounds of this invention, as well as multi-component compositions comprising additional IMPDH compounds together with an immunosuppressant .
  • the invention also provides methods of using the compounds of this invention, as well as other related compounds, for the inhibition of IMPDH.
  • -SO2- and “-S(0)2-" ss used herein refer to a sulfone or sulfone derivative (i.e., both appended groups linked to the S) , and not a sulfinate ester.
  • halo or “halogen” refer to a radical of fluorine, chlorine, bromine or iodine.
  • immunosuppressant refers to a compound or drug which possesses immune response inhibitory activity.
  • agents include cyclosporin A, FK506, rapamycin, leflunomide, deoxyspergualin, prednisone, azathioprine, mycophenolate mofetil, 0KT3 , ATAG, interferon and mizoribine.
  • interferon refers to all forms of interferons, including but not limited to alpha, beta and gamma forms.
  • IMPDH-mediated disease refers to any disease state in which the IMPDH enzyme plays a regulatory role in the metabolic pathway of that disease.
  • IMPDH-mediated disease include transplant rejection and autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis, juvenile diabetes, asthma, and inflammatory bowel disease, as well as inflammatory diseases, cancer, viral replication diseases and vascular diseases .
  • the compounds, compositions and methods of using them of this invention may be used in the treatment of transplant rejection (e.g., kidney, liver, heart, lung, pancreas (islet cells) , bone marrow, cornea, small bowel and skin allografts and heart valve xenografts), rheumatoid arthritis, multiple sclerosis, juvenile diabetes, asthma, inflammatory bowel disease (Crohn's disease, ulcerative colitis), lupus, diabetes, mellitus myasthenia gravis, psoriasis, dermatitis, eczema, seborrhea, pulmonary inflammation, eye uveiti ⁇ , hepatitis, Grave's disease, Hashimoto's thyroiditi ⁇ , Behcet's or Sjorgen's syndrome (dry eyes/mouth) , pernicious or immunohaemolytic anaemia, idiopathic adrenal insufficiency, polyglandular autoimmune syndrome, and glomerulonep
  • IMPDH enzymes are also known to be present in bacteria and thus may regulate bacterial growth.
  • the IMPDH-inhibitor compounds, compositions and methods described herein may be useful in treatment or prevention of bacterial infection, alone or in combination with other antibiotic agents.
  • treating refers to the alleviation of symptoms of a particular disorder in a patient or the improvement of an ascertainable measurement associated with a particular disorder.
  • patient refers to a mammal, including a human.
  • HBV hepatitis-B virus
  • HCV hepatitis-C virus
  • HGV hepatitis-G virus
  • the invention provides compounds of formula I : R2
  • X is selected from -C (0) -N (R 6 ) - , -N (R 6 ) -C (0) - , -CH 2 - N(R 6 )-, -N(R 6 )-CH 2 -, -N(R 6 )-S(0) 2 -, -S (0) 2 -N (R 6 ) - ,
  • each R 6 is independently selected from hydrogen, d- C 4 straight or branched alkyl, C -C 4 straight or branched alkenyl or alkynyl, Ar-substituted-C ⁇ -C 4 straight or branched alkyl, or Ar-substituted-C-C 4 straight or branched alkenyl or alkynyl ; wherein
  • Re is optionally substituted with up to 3 substituents independently selected from halo, hydroxy, nitro, cyano or amino; each R 12 is independently selected from R 6 , W- [C 1 -C 4 straight or branched alkyl], W-[C 2 -C 4 straight or branched alkenyl or alkynyl], Ar-substituted- [W- [C 1 -C 4 straight or branched alkyl]], Ar-substituted- [W- [C 2 -C straight or branched alkenyl or alkynyl]], 0-Ar, N(R 6 )-Ar, S-Ar, S(0)- Ar, S(0) 2 -Ar, S-C(0)H, N(R 6 )-C(0)H, or 0-C(0)H; wherein
  • W is 0-, 0-C(0)-, S-, S(0)-, S(0) 2 -, S-C(0)-, N(R 6 )-, or N(R 6 )-C(0)-; and wherein each R 12 is optionally and independently substituted with up to 3 substituents independently selected from halo, hydroxy, nitro, cyano or amino. - 10 -
  • Q is selected from 0, -0-C(0)-, -C(0)-0-, -N(H)-C(0)-0-, -0-N(H)-C(0)-, -N(H)-C(0)-, -C(0)-N(H)-, -0-C(0)-N(H)-, or -C(0)-N(H)-0-;
  • Ar is selected from phenyl, 1-naphthyl, 2-naphthyl, indenyl, azulenyl, fluorenyl, anthracenyl, 2-furyl, 3- furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4- pyridyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyraxolyl, 2-pyrazolinyl, pyrazolidinyl, isoxazolyl, isotriazolyl, 1, 2
  • R ⁇ is selected from [C ⁇ -C ⁇ straight or branched alkyl] or, [C 2 -C ⁇ 2 straight or branched alkenyl or alkynyl] ; wherein R i3 is optionally substituted with 1 to 4 substituents independently selected from R ⁇ 4 or R 15 , wherein each Ri 4 is a monocyclic or a bicyclic ring system consisting of 3 to 7 members per ring, wherein said ring system optionally comprises up to 4 heteroatoms selected from N, 0, or S; wherein a CH 2 adjacent to said N, O or S maybe substituted with C(O); and wherein R i4 optionally comprises up to 2 substituents independently selected from (Ci-C 4 ) -straight or branched alkyl, (C 2 -C 4 ) straight or branched alkenyl, 1 , 2-methylenedioxy, 1,2- ethylenedioxy, (CH 2 ) n -R 16 , -S- (CH 2 ) n -
  • Ri 6 is selected from halogen, -CN, -N0 2 , -CF 3 , -0CF 3 , -OH, -S-(Ci-C 4 ) -alkyl, -S (0) - (C ⁇ -C 4 ) -alkyl , -S (0) 2 - (C ⁇ C - alkyl, -NH 2 , -NH- (C ⁇ -C 4 ) -alkyl , N ( (Ci-C 4 ) -alkyl ) 2 , COOH, C(0)-0-(Cj . -C 4 ) -alkyl or 0- (C ⁇ -C 4 ) -alkyl ; and - 12 -
  • each R 15 is independently selected from -ORj .7 , or -N(R ⁇ 8 ) 2 ;
  • R17 is selected from hydrogen, - (C ⁇ -C 6 ) -straight alkyl, - (C ⁇ -C 6 ) -straight alkyl-Ar, -C (0) - (C ⁇ -C 6 ) -straight or branched alkyl, -C(0)-Ar, or - (C ⁇ -C 6 ) -straight alkyl - CN; and each Rig is independently selected from -(C ⁇ -C 6 )- straight or branched alkyl, - (C ⁇ -C 6 ) -straight or branched alkyl-Ar, - (C ⁇ -C 6 ) -straight alkyl-CN, - (C ⁇ -C 6 ) -straight alkyl-OH, - (C ⁇ -C 6 ) -straight alkyl-0R 17 , -C (0) - (C ⁇ -C 6 ) - straight or branched alkyl, -C(0)-Ar,
  • R 2 , R 3 , R , or R 5 is hydrogen; no more than two of Ri, R 2 , R 3 , R 4 , or R 5 comprises Ar; at least two of R 7 , R e , R 9 , Rio or R u is hydrogen; and no more than two of R 7 , R 8 , R 9 ⁇ R 10 or R comprises
  • the compounds of this invention specifically exclude those wherein X is -NH-S(0) 2 - or -S (0) 2 -N(H) - , one of Ri, R 2 , R 3 , R 4 , R 5 , R 7 , R 8 , Rg, Rio or Rn is 0-(d-C 4 )- straight or branched alkyl, seven of Ri , R2, R 3 , R , Rs, R7, R 8 , R 9 , Rio or Rn is hydrogen and the remaining two of Ri, R2, R 3 , R , R5, R7, R 8 - R9, Rio or Rn are bound together to form a 5 to 6-membered aromatic carbocyclic or heterocyclic ring.
  • X is -NH-S(0) 2 - or -S (0) 2 -N (H) - , two of R x , R 2
  • R 8 , Rg, Rio or Rn are 0- (C ⁇ -C 4 ) -straight or branched alkyl, seven of R ⁇ , R 2 , R 3 , R 4 , R5, R7, Rs, R9, Rio or Rn is hydrogen and the remaining one of Ri, R 2 , R 3 , R 4 , R 5 , R 7 , R 8 , R 9 , Rio or Rn is -N0 2 , -CN or -Ar.
  • Another set of compounds excluded from the present invention are those wherein X is -NH-S(0) 2 - or - S(0) 2 -N(H)-, two of Ri, R 2 , R 3 , R 4 , R5, R7, Rs , Rg, Rio or Rn are 0- (C ⁇ -C 4 ) -straight or branched alkyl, six of Ri, R 2 , R 3 , R 4 , R5, R7, Rs , R9, Rio or Rn is hydrogen and the remaining two of Ri, R 2 , R 3 , R 4 , R5, R 7 , Rs, R9, Rio or Rn are both halo.
  • Yet another set of compounds excluded are those wherein X is -NH-S(0) 2 - or -S (0) 2 -N(H) - , one of R ⁇ , R 2 , R 3 , R 4 , R 5 , R 7 , R 8 , R 9 , Rio or Rn is Ar and the remaining 9 of Ri, R 2 , R 3 , R 4 , R 5 , R , R 8 , Rg, Rio or Rn are each hydrogen.
  • Another set of excluded compounds are those wherein X is -N(H) -C (0) -S- or -S-C (0) -N(H) - , one of R l t R2, R 3 , R 4 , R5, R 7 , Rs, Rg, Rio or Rn is -OH, eight of R l t R 2 , R 3 , R 4 , R 5 , R7, Rs, Rg, Rio or Rn are hydrogen and the remaining one of Ri , R 2 , R 3 , R 4 , R5, R7, Rs , Rg, Rio or Rn is halo; and those wherein X is - (H) -C (0) -S- or -S-C(O)- N(H)-, one of R l t R 2 , R 3 , R 4 , R 5 , R 7 , Rs, Rg, Rio or R ⁇ is - 14 -
  • R lr R 2 , R 3 , R 4 , R 5 , R 7 , Rs, Rg, Rio or Rn are hydrogen, one of Ri, R 2 , R3 , R 4 , R5 , R7 , Rs, Rg, Rio or Rn is 0- (C ⁇ C ) -straight or branched alkyl and the remaining one of Ri, R 2 R 3 , R 4 , R 5 , R 7 , R 8 , R 9, R 10 or R ⁇ is halo or (C ⁇ C 4 ) -straight or branched alkyl.
  • heterocyclic ring refers to a ring which comprises 1 to 4 heteroatoms independently selected from N, O or S .
  • Ar-substituted- (C1-C4) -straight or branched alkyl and “Ar-substituted- (C 2 -C 4 ) -straight or branched alkenyl or alkynyl” denote that one or more Ar groups may be attached to the alkyl, alkenyl or alkynyl chain at any chemically feasible position on the chain, including the termini .
  • references to "[branched alkyl, alkenyl or alkynyl] -Ar” or "[branched alkyl, alkenyl or alkynyl] -Q- Ar” denote that an “Ar” or "Q-Ar” moiety is attached to one or more terminal ends of the branched alkyl, alkenyl or alkynyl chain.
  • X is selected from -C(0)-N(R 6 ) -, -N (R 6 ) -C (0) - , -CH 2 -N(R 6 )-, or -N(R 6 )-CH 2 - or -N(R 6 ) -C(O) -Y . More preferably, X is - 15 -
  • R is selected from H, (C ⁇ -C 4 ) -straight or branched alkyl, OH, 0- (C ⁇ -C 4 ) -straight or branched alkyl, 0-Ar, 0CF 3 , halo, cyano or S- (C ⁇ -C 4 ) -straight or branched alkyl.
  • Ri is H when R 2 is not H.
  • R 2 is preferably selected from H, (C 1 -C 4 )- straight or branched alkyl, Ar, 0- (C 1 -C 4 ) -straight or branched alkyl, 0-Ar, 0CF 3 , halo, cyano, C(0)NH 2 or S(0) 2 -
  • R 2 is H.
  • R 3 is preferably selected from H, Ar, cyano, O-
  • R 4 is selected from H, (C1-C4) -straight or branched alkyl, OH, 0-(C ⁇ -C 4 )- straight or branched alkyl, 0-Ar, OCF 3 , halo, cyano or S-
  • R 5 is preferably selected from H, (C 1 -C 4 )- ⁇ traight or branched alkyl, Ar, 0- (C 1 -C 4 ) -straight or branched alkyl, O-Ar, 0CF 3 , halo, cyano, C(0)NH 2 or S(0) 2 -
  • R 7 is selected from H, OH, OC (0) - (C 1 -C 4 ) -straight or branched alkyl, 0- (C ⁇ -C ) -straight or branched alkyl, O-Ar, amino, or N(H)C(0) - (C 1 -C 4 ) -straight or branched alkyl. Even more preferred is when R 7 is OH.
  • R 8 is preferably H, (C ⁇ -C 4 ) -straight or branched alkyl, 0- (C ⁇ -C 4 ) -straight or branched alkyl, or (C 1 -C 4 )- straight or branched alkyl-N (H) C (0) 0-Ar . - 16 -
  • R 9 is selected from H, (C 1 -C 4 ) -straight or branched alkyl, 0- (C ⁇ -C 4 ) -straight or branched alkyl, or R 9 is taken together with Rio and the carbon atoms to which they are bound to form a fused benzene ring. More preferred is when Rg and Rio are taken together with the carbon atoms to which they are bound to form a fused benzene ring.
  • R 10 is selected from H, (C 1 -C 4 ) -straight or branched alkyl, 0- (C1-C4) -straight or branched alkyl, or Rio is taken together with R 9 and the carbon atoms to which they are bound to form a fused benzene ring.
  • Rn is selected from H, OH, OC (0) - (C 1 -C 4 ) -straight or branched alkyl, 0- (C1-C4) -straight or branched alkyl, O-Ar, amino, or N(H)C(0) - (C 1 -C 4 ) -straight or branched alkyl. More preferably, R X1 is H.
  • Q is -N(H)-C(0)-0-.
  • preferred compounds of the invention are listed in the table below.
  • the compounds of this invention may contain one or more asymmetric carbon atoms and thus may occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers . All such isomeric forms of these compounds are expressly included in the present invention.
  • Each stereogenic carbon may be of the R or S configuration.
  • stable refers to compounds which possess stability sufficient to allow manufacture and which maintains the integrity of the compound for a sufficient period of time to be useful for the purposes detailed herein (e.g., therapeutic or prophylactic administration to a mammal or for use in affinity chromatography applications) .
  • such compounds are stable at a temperature of 40°C or less, in the absence of moisture or other chemically reactive conditions, for at least a week.
  • the compounds of this invention are defined to include pharmaceutically acceptable derivatives or prodrugs thereof .
  • a "pharmaceutically acceptable derivative or prodrug” means any pharmaceutically acceptable salt, ester, salt of an ester, or other derivative of a compound of this invention which, upon administration to a recipient, is capable of providing (directly or indirectly) a compound of this invention.
  • Particularly favored derivatives and prodrugs are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a mammal (e.g., by allowing an orally - 40 -
  • prodrugs include derivatives where a group which enhances aqueous solubility or active transport through the gut membrane is appended to the structure of the compounds of this invention.
  • Pharmaceutically acceptable salts of the compounds of this invention include those derived from pharmaceutically acceptable inorganic and organic acids and bases.
  • suitable acid salts include acetate, adipate, alginate, aspartate, benzoate, benzene sulfonate, bisulfate, butyrate, citrate, camphorate, camphor sulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-pheny
  • Base salts include ammonium salts, alkali metal salts, such as sodium and potassium salts, alkaline earth metal salts, such as calcium and magnesium salts, salts with organic bases, such as dieyelohexylamine salts, N-methyl-D- glucamine, and salts with amino acids such as arginine, lysine, and so forth.
  • the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, - 41 -
  • dialkyl sulfates such as dimethyl, diethyl, dibutyl and dia yl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides, such as benzyl and phenethyl bromides and others. Water or oil-soluble or dispersible products are thereby obtained.
  • the compounds of this invention may be synthesized using conventional techniques.
  • these compounds are conveniently synthesized from readily available starting materials.
  • a in the initial step was -N(H)R 6 and B was -C(0)OH or -C(0)C1.
  • the coupling was performed in the presence of EDC, HOAt and CH 3 CN.
  • a in the initial step was -N(H)R 6 and B was -Y-C(0)OH or -Y-C(0)C1.
  • the coupling was performed in the presence of EDC, CH 2 Cl 2 and DMAP.
  • a in the initial step was N(H)R 6 and B was S(0) 2 C1.
  • the coupling was performed in the presence of TEA and CH 2 C1 2 .
  • a in the initial step was N(H)R 6 and B was 0C(0)C1.
  • the coupling was performed in the presence of TEA and CH 2 C1 2 .
  • a in the initial step was NC(0) and B was SH.
  • the coupling was performed in the presence of DMAP and CH 2 C1 2 .
  • the procedure is as follows :
  • Event Volume Flow rate condition sorbent 1.5 ml 3 mL/min load and collect 0.9 ml 3 mL/min elute 1.5 ml 1 mL/min
  • the collected solution contained product at >95% purity (HPLC: 210 nm) with traces of O-acylated impurity. Yields were typically 8-12 mg.
  • the compounds of this invention may be modified by appending appropriate functionalities to enhance selective biological properties.
  • modifications are known in the art and include those which increase biological penetration into a given biological compartment (e.g., blood, lymphatic system, central nervous system) , increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion.
  • novel compounds of the present invention are excellent ligands for IMPDH. Accordingly, these compounds are capable of targeting and inhibiting IMPDH - 44 -
  • Inhibition can be measured by various methods, including, for example, IMP dehydrogenase HPLC assays (measuring enzymatic production of XMP and NADH from IMP and NAD) and IMP dehydrogenase spectrophotometric assays (measuring enzymatic production of NADH from NAD) .
  • IMP dehydrogenase HPLC assays measuring enzymatic production of XMP and NADH from IMP and NAD
  • IMP dehydrogenase spectrophotometric assays measuring enzymatic production of NADH from NAD
  • compositions of this invention comprise a compound of this invention or a salt thereof; an additional agent selected from an immunosuppressant, an anti-cancer agent, an anti-viral agent, anti-inflammatory agent, antifungal agent, antibiotic, or an anti-vascular hyperproliferation compound; and any pharmaceutically acceptable carrier, adjuvant or vehicle.
  • Alternate compositions of this invention comprise a compound of this invention or a salt thereof; and a pharmaceutically acceptable carrier, adjuvant or vehicle.
  • Such composition may optionally comprise an additional agent selected from an immunosuppressant, an anti-cancer agent, an anti-viral agent, anti-inflammatory agent, antifungal agent, antibiotic, or an anti-vascular hyperproliferation compound.
  • the compositions of this invention are pharmaceutical compositions .
  • pharmaceutically acceptable carrier or adjuvant refers to a carrier or adjuvant that may be administered to a patient, together with a compound of this invention, and which does not destroy the pharmacological activity thereof and is nontoxic when administered in doses sufficient to deliver a therapeutic amount of the compound.
  • compositions that may be used in the pharmaceutical - 45 -
  • compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d ⁇ -tocopherol polyethyleneglycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates , waxes, polyethylene-polyoxypropylene-block polymers , polyethylene glycol and wool
  • Cyclodextrins such as cc-, ⁇ -, and ⁇ -cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3-hydroxypropyl- ⁇ -cyclodextrins, or other solubilized derivatives may also be advantageously used to enhance delivery of compounds of this invention.
  • the pharmaceutical compositions of this invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. We prefer oral administration or administration by injection.
  • the pharmaceutical compositions of this invention may contain any conventional non-toxic pharmaceutically-acceptable carriers, adjuvants or vehicles. In some cases, the pH of the formulation may be adjusted with pharmaceutically - 46 -
  • parenteral as used herein includes subcutaneous, intracutaneous , intravenous, intramuscular, intra-articular, intraarterial , intrasynovial , intrasternal , intrathecal, intralesional and intracranial injection or infusion techniques.
  • compositions may be in the form of a sterile injectable preparation, for example, as a sterile injectable aqueous or oleaginous suspension.
  • This suspension may be formulated according to techniques known in the art using suitable dispersing or wetting agents (such as, for example, Tween 80) and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1 , 3-butanediol .
  • suitable vehicles and solvents that may be employed are mannitol, water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides .
  • Fatty acids such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.
  • oils such as olive oil or castor oil, especially in their polyoxyethylated versions.
  • These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant such as those described in Pharmacopeia Helvetica, Ph. Helv. , or a similar alcohol, or carboxymethyl cellulose or similar dispersing agents which are commonly used in the - 47 -
  • compositions such as emulsions and or suspensions
  • Other commonly used surfactants such as Tweens or Spans and/or other similar emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
  • compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, emulsions and aqueous suspensions, dispersions and solutions.
  • carriers which are commonly used include lactose and corn starch.
  • Lubricating agents such as magnesium stearate, are also typically added.
  • useful diluents include lactose and dried corn starch.
  • compositions of this invention may also be administered in the form of suppositories for rectal administration.
  • These compositions can be prepared by mixing a compound of this invention with a suitable non-irritating excipient which is solid at room temperature but liquid at the rectal temperature and therefore will melt in the rectum to release the active components.
  • suitable non-irritating excipient include, but are not limited to, cocoa butter, beeswax and polyethylene glycols . - 48 -
  • Topical administration of the pharmaceutical compositions of this invention is especially useful when the desired treatment involves areas or organs readily accessible by topical application.
  • the pharmaceutical composition should be formulated with a suitable ointment containing the active components suspended or dissolved in a carrier.
  • Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petroleum, white petroleum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water.
  • the pharmaceutical composition can be formulated with a suitable lotion or cream containing the active compound suspended or dissolved in a carrier with suitable emulsifying agents.
  • Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
  • the pharmaceutical compositions of this invention may also be topically applied to the lower intestinal tract by rectal suppository formulation or in a suitable enema formulation. Topically-transdermal patches are also included in this invention.
  • the pharmaceutical compositions of this invention may be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, - 49 -
  • fluorocarbons and/or other solubilizing or dispersing agents known in the art .
  • Dosage levels of between about 0.01 and about 100 mg/kg body weight per day, preferably between about 0.5 and about 75 mg/kg body weight per day of the IMPDH inhibitory compounds described herein are useful in a monotherapy and/or in combination therapy for the prevention and treatment of IMPDH mediated disease.
  • the pharmaceutical compositions of this invention will be administered from about 1 to about 5 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy.
  • the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. A typical preparation will contain from about 5% to about 95% active compound (w/w) .
  • compositions of this invention comprise a combination of an IMPDH inhibitor of this invention and one or more additional therapeutic or prophylactic agents
  • both the IMPDH inhibitor and the additional agent should be present at dosage levels of between about 10 to 100%, and more preferably between about 10 to 80% of the dosage normally administered in a monotherapy regimen.
  • the additional agents may be administered separately, as part of a multiple dose regimen, from the compounds of this invention. Alternatively, those agents may be part of a single dosage form, mixed together with the compounds of this invention in a single composition. - 50 -
  • the pharmaceutical compositions of this invention comprise an additional immunosuppression agent.
  • additional immunosuppression agents include, but are not limited to, cyclosporin A, FK506, rapamycin, leflunomide, deoxyspergualin, prednisone, azathioprine, mycophenolate mofetil, OKT3 , ATAG, interferon and mizoribine.
  • the pharmaceutical compositions of this invention may additionally comprise an anti-cancer agent.
  • anti-cancer agents include, but are not limited to, cis- platin, actinomycin D, doxorubicin, vincristine, vinblastine, etoposide, amsacrine, mitoxantrone, tenipaside, taxol, colchicine, cyclosporin A, phenothiazines , interferon and thioxantheres .
  • compositions of this invention may additionally comprise an anti-viral agent.
  • anti-viral agents include, but are not limited to, Cytovene, Ganciclovir, trisodium phosphonoformate,
  • Ribavirin, d4T, ddl, AZT, and acyclovir Ribavirin, d4T, ddl, AZT, and acyclovir.
  • the pharmaceutical compositions of this invention may additionally comprise an anti-vascular hyperproliferative agent.
  • anti-vascular hyperproliferative agents include, but are not limited to, HMG Co-A reductase inhibitors such as lovastatin, thromboxane A2 synthetase inhibitors, eicosapentanoic acid, ciprostene, trapidil, ACE inhibitors, low molecular weight heparin, mycophenolic acid, rapamycin and 5-(3'- pyridinylmethyl)benzofuran-2-carboxylate. - 51 -
  • a maintenance dose of a compound, composition or combination of this invention may be administered, if necessary. Subsequently, the dosage or frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level, treatment should cease. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.
  • this invention provides methods of treating or preventing IMPDH mediated disease in a mammal comprising the step of administrating to said mammal any of the pharmaceutical compositions and combinations described above. If the pharmaceutical composition only comprises the IMPDH inhibitor of this invention as the active component, such methods may additionally comprise the step of administering to said mammal an agent selected from an anti-inflammatory agent, immunosuppressant, an anti-cancer agent, an anti-viral agent, or an anti-vascular hyperproliferation compound. Such additional agent may be administered to the mammal - 52 -
  • these methods are useful in suppressing an immune response in a mammal.
  • Such methods are useful in treating or preventing diseases, including, transplant rejection (e.g., kidney, liver, heart, lung, pancreas (islet cells), bone marrow, cornea, small bowel and skin allografts and heart valve xenografts) , graft versus host disease, and autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis, juvenile diabetes, asthma, inflammatory bowel disease (Crohn's disease, ulcerative colitus), lupus, diabetes, mellitus myasthenia gravis, psoriasis, dermatitis, eczema, seborrhea, pulmonary inflammation, eye uveitis, Grave's disease, Hashimoto's thyroiditis, Behcet's or Sjorgen's syndrome (dry eyes /mout ) , pernicious or immunohaemolytic anaemia,
  • transplant rejection
  • these methods comprise the step of administering to the mammal a composition comprising a compound of this invention and a pharmaceutically acceptable adjuvant.
  • this particular method comprises the additional step of administering to said mammal a composition comprising an additional immunosuppressant and a pharmaceutically acceptable adjuvant.
  • this method comprises the step of administering to said mammal a composition comprising a compound of this invention; an additional - 53 -
  • immunosuppressive agent and a pharmaceutically acceptable adjuvant .
  • these methods are useful for inhibiting viral replication in a mammal.
  • Such methods are useful in treating or preventing DNA and RNA viral diseases caused by infection for example, by orthomyxoviruses (influenza viruses types A and B) , paramyxoviruses (respiratory syncytial virus (RSV) , subacute sclerosing panencephalitis (SSPE) virus) measles and parainfluenza type 3), herpesviruses (HSV-1, HSV-2, HHV-6, HHV-7, HHV-8, Epstein Barr Virus (EBV) , cytomegalovirus (HCMV) and varicella zoster virus (VZV) ) , retroviruses (HIV-1, HIV-2, HTLV-1, HTLV-2), flavi- and pestiviruses (yellow fever virus (YFV) , hepatitis C virus (HCV) , dengue fever virus, bovine viral diarrhea virus
  • RVFV sandfly fever Sicilian virus
  • Hantaan virus Caraparu virus
  • human papilloma viruses human papilloma viruses
  • encephalitis viruses La Crosse virus
  • arena viruses Junin and Tacaribe virus
  • reovirus vesicular stomatitis virus
  • rhinoviruses enteroviruses
  • enteroviruses polio virus, coxsackie viruses, encephalomyocarditis virus (EMC)
  • Lassa fever virus and togaviruses (Sindbis and Semlike forest viruses) and poxviruses (vaccinia virus), adenoviruses, rubiola, and rubella.
  • These methods comprise the step of administering to the mammal a composition comprising a compound of this invention, and a pharmaceutically - 54 -
  • this particular method comprises the additional step of administering to said mammal a composition comprising an additional anti-viral agent and a pharmaceutically acceptable adjuvant.
  • this method comprises the step of administering to said mammal a composition comprising a compound of this invention; an additional anti-viral agent and a pharmaceutically acceptable adjuvant.
  • these methods are useful for inhibiting vascular cellular hyperproliferation in a mammal. Such methods are useful in treating or preventing diseases, including, restenosis, stenosis, artherosclerosis and other hyperproliferative vascular disease.
  • these methods comprise the step of administering to the mammal a composition comprising a compound of this invention, and a pharmaceutically acceptable adjuvant.
  • this particular method comprises the additional step of administering to said mammal a composition comprising an additional anti-vascular hyperproliferative agent and a pharmaceutically acceptable adjuvant.
  • this method comprises the step of administering to said mammal a composition comprising a compound of this invention; an additional anti-vascular hyperproliferative agent and a pharmaceutically acceptable adjuvant.
  • these methods are useful for inhibiting tumors and cancer in a mammal .
  • Such methods are useful in treating or - 55 -
  • diseases including, tumors and malignancies, such as lymphoma, leukemia and other forms of cancer.
  • these methods comprise the step of administering to the mammal a composition comprising a compound of this invention, and a pharmaceutically acceptable adjuvant.
  • this particular method comprises the additional step of administering to said mammal a composition comprising an additional anti-tumor or anti-cancer agent and a pharmaceutically acceptable adjuvant.
  • this method comprises the step of administering to said mammal a composition comprising a compound of this invention; an additional anti-tumor or anti-cancer agent and a pharmaceutically acceptable adjuvant.
  • these methods are useful for inhibiting inflammation and inflammatory diseases in a mammal .
  • Such methods are useful in treating or preventing diseases, including, osteoarthritis, acute pancreatitis, chronic pancreatitis, asthma and adult respiratory distress syndrome.
  • these methods comprise the step of administering to the mammal a composition comprising a compound of this invention, and a pharmaceutically acceptable adjuvant.
  • this particular method comprises the additional step of administering to said mammal a composition comprising an anti-inflammatory agent and a pharmaceutically acceptable adjuvant .
  • IMP dehydrogenase activity was assayed following an adaptation of the method first reported by Magasanik. [B. Magasanik et al . , J. Biol. Chem. , 226, p. 339 (1957), the disclosure of which is herein incorporated by reference] . Enzyme activity was measured spectrophotometrically, by monitoring the increase in absorbance at 340 nm due to the formation of NADH ( ⁇ 340 is 6220 M -1 c ⁇ l) .
  • the reaction mixture contained 0.1 M Tris pH 8.0, 0.1 M KCl, 3 mM EDTA, 2 mM DTT, 0.1 M IMP and enzyme (IMPDH human type II) at a concentration of 15 to 50 nM. This solution is incubated at 37°C for 10 minutes. The reaction is started by adding NAD to a final concentration of 0. IM and the initial rate is measured by following the linear increase in absorbance at 340 nm for 10 minutes. For reading in a standard spectrophotometer (path length 1 cm) the final volume in the cuvette is 1.0 ml. The assay has also been adapted to a 96 well microtiter plate format; in this case the concentrations of all the reagents remain the same and the final volume is decreased to 200 ⁇ l .
  • the compound in question is dissolved in DMSO to a final concentration of 20 mM and added to the initial assay mixture for preincubation with the enzyme at a final volume of 2- 5% (v/v) .
  • the reaction is started by the addition of NAD, and the initial rates measured as above.
  • K-j_ determinations are made by measuring the initial velocities in the presence of varying amounts of inhibitor and fitting the data using the tight-binding - 61 -
  • Category "A” indicates a Ki of less than 10 ⁇ M
  • category “B” indicates a K ⁇ of between 10 and 20 ⁇ M
  • category “C” indicates a K ⁇ greater than 20 ⁇ M.
  • the anti-viral efficacy of compounds may be evaluated in various _in vitro and _in vivo assays.
  • compounds may be tested in _in vitro viral replication assays.
  • Xn vitro assays may employ whole cells or isolated cellular components.
  • Xn vivo assays include animal models for viral diseases. Examples of such animal models include, but are not limited to, rodent models for HBV or HCV infection, the Woodchuck model for HBV infection, and chimpanzee model for HCV infection.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention se rapporte à des composés qui inhibent l'IMPDH ainsi qu'à des compositions pharmaceutiques contenant ces composés. Lesdits composés et compositions pharmaceutiques conviennent particulièrement pour inhiber l'activité de l'enzyme IMPDH et peuvent avantageusement servir en tant qu'agents thérapeutiques pour les processus à médiation assurée pat cet enzyme IMPDH. L'invention se rapporte également à des procédés visant à inhiber l'activité de l'enzyme IMPDH au moyen des composés décrits ci-dessus et de composés associés.
PCT/US1999/009005 1998-04-29 1999-04-26 Inhibiteurs de l'enzyme impdh WO1999055663A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP99918831A EP1076641A1 (fr) 1998-04-29 1999-04-26 Inhibiteurs de l'enzyme impdh
JP2000545824A JP2002512997A (ja) 1998-04-29 1999-04-26 Ｉｍｐｄｈ酵素のインヒビター
AU36651/99A AU3665199A (en) 1998-04-29 1999-04-26 Inhibitors of impdh enzyme
US09/702,991 US6653309B1 (en) 1999-04-26 2000-10-30 Inhibitors of IMPDH enzyme technical field of the invention
US10/671,967 US7989498B2 (en) 1999-04-26 2003-09-25 Inhibitors of IMPDH enzyme

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8338598P 1998-04-29 1998-04-29
US60/083,385 1998-04-29

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/702,991 Continuation US6653309B1 (en) 1999-04-26 2000-10-30 Inhibitors of IMPDH enzyme technical field of the invention

Publications (1)

Publication Number Publication Date
WO1999055663A1 true WO1999055663A1 (fr) 1999-11-04

Family

ID=22177967

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/009005 WO1999055663A1 (fr) 1998-04-29 1999-04-26 Inhibiteurs de l'enzyme impdh

Country Status (4)

Country Link
EP (1) EP1076641A1 (fr)
JP (1) JP2002512997A (fr)
AU (1) AU3665199A (fr)
WO (1) WO1999055663A1 (fr)

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1127054A1 (fr) * 1998-10-29 2001-08-29 Bristol-Myers Squibb Company Nouveaux inhibiteurs de l'enzyme impdh
WO2002022565A1 (fr) * 2000-09-15 2002-03-21 Iconix Pharmaceuticals, Inc. Inhibiteurs de rho c
US6399773B1 (en) 1998-10-29 2002-06-04 Bristol-Myers Squibb Co. Compounds derived from an amine nucleus that are inhibitors of IMPDH enzyme
WO2002050045A1 (fr) * 2000-12-18 2002-06-27 Biota Scientific Management Pty Ltd Agents antiviraux
US6420403B1 (en) 1998-10-29 2002-07-16 Edwin J. Iwanowicz Inhibitors of IMPDH enzyme
US6596747B2 (en) 1998-10-29 2003-07-22 Bristol-Myers Squibb Company Compounds derived from an amine nucleus and pharmaceutical compositions comprising same
EP1352650A1 (fr) * 2000-12-18 2003-10-15 Institute of Medicinal Molecular Design, Inc. Inhibiteurs de production et de liberation de cytokines inflammatoires
US6653309B1 (en) 1999-04-26 2003-11-25 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme technical field of the invention
WO2003103655A1 (fr) * 2002-06-10 2003-12-18 株式会社医薬分子設計研究所 Agent therapeutique pour soigner le cancer
WO2003103665A1 (fr) * 2002-06-06 2003-12-18 株式会社医薬分子設計研究所 Anti-allergique
EP1453470A1 (fr) * 2001-11-19 2004-09-08 Iconix Pharmaceuticals, Inc. Modulateurs de l'activite de rho c
WO2004108673A2 (fr) * 2003-06-09 2004-12-16 Boehringer Ingelheim International Gmbh Inhibiteurs du papillomavirus
EP1487796A1 (fr) * 2002-03-28 2004-12-22 Neurogen Corporation Biarylamides substitues en tant que modulateurs du recepteur c5a
WO2005021721A2 (fr) * 2003-08-29 2005-03-10 St. Jude Children's Research Hospital Inhibiteurs de la carboxylesterase
US6867299B2 (en) 2000-02-24 2005-03-15 Hoffmann-La Roche Inc. Oxamide IMPDH inhibitors
US6939885B2 (en) 2002-11-18 2005-09-06 Chemocentryx Aryl sulfonamides
WO2005085234A3 (fr) * 2004-03-03 2006-01-26 Syngenta Participations Ag Nouveaux insecticides
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
WO2006120178A1 (fr) * 2005-05-11 2006-11-16 Novo Nordisk A/S Nouveaux composes d'haloalkylsulfone substitues utiles dans le traitement de l'obesite et de diabetes
WO2006125778A1 (fr) * 2005-05-23 2006-11-30 Novo Nordisk A/S Nouveaux aryl-anilides a substitution trifluoromethoxy
US7148225B2 (en) 2002-03-28 2006-12-12 Neurogen Corporation Substituted biaryl amides as C5A receptor modulators
US7166738B2 (en) 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
WO2007030617A1 (fr) * 2005-09-09 2007-03-15 Vertex Pharmaceuticals Incorporated Inhibiteurs d'inosine-5'-monophosphate deshydrogenase (impdh) bacterienne
US7227035B2 (en) 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
US7321001B2 (en) 2002-12-20 2008-01-22 Amgen Inc. Asthma and allergic inflammation modulators
US7388111B2 (en) 2005-10-19 2008-06-17 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
US7420055B2 (en) 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
US7547804B2 (en) 2002-07-15 2009-06-16 Myriad Genetics, Inc. Compounds, compositions, and methods employing same
US7625949B2 (en) 2004-04-23 2009-12-01 Roche Palo Alto Llc Methods for treating retroviral infections
US7671058B2 (en) 2006-06-21 2010-03-02 Institute Of Medicinal Molecular Design, Inc. N-(3,4-disubstituted phenyl) salicylamide derivatives
EP2181704A2 (fr) 2002-12-30 2010-05-05 Angiotech International Ag Liberation de medicaments a partir d'une compostion polymere a gelification rapide
US7999109B2 (en) 2002-05-24 2011-08-16 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
US20110301179A1 (en) * 2008-10-21 2011-12-08 Xiangshu Xiao Naphthamides as anticancer agents
US8084614B2 (en) 2007-04-06 2011-12-27 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
EP2411529A2 (fr) * 2009-03-27 2012-02-01 Zacharon Pharmaceuticals, Inc. Modulateurs de la biosynthèse des glycanes n-liés
US8168658B2 (en) 2006-02-28 2012-05-01 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase
US8183293B2 (en) 2007-12-19 2012-05-22 Amgen Inc. Phenyl acetic acid derivatives
US8263588B2 (en) 2007-04-06 2012-09-11 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
US8466180B2 (en) 2006-09-11 2013-06-18 Syngenta Crop Protection Llc Insecticidal compounds
US8642808B2 (en) 2002-11-18 2014-02-04 Chemocentryx, Inc. Bis-aryl sulfonamides
US9126944B2 (en) 2013-02-28 2015-09-08 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
US9828345B2 (en) 2013-02-28 2017-11-28 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
JP2018027960A (ja) * 2009-12-10 2018-02-22 トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク ヒストンアセチルトランスフェラーゼ活性化剤及びその使用
US9969677B2 (en) 2010-12-22 2018-05-15 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase modulators and uses thereof
US10640457B2 (en) 2009-12-10 2020-05-05 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
US10647661B2 (en) 2017-07-11 2020-05-12 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
EP4167999A4 (fr) * 2020-06-19 2024-03-06 Endogena Therapeutics Inc Nouveaux composés et leur utilisation en tant que substances thérapeutiquement actives dans le traitement et/ou la prévention de maladies impliquant l'épithélium pigmentaire rétinien

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0526252D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0722779D0 (en) * 2007-11-20 2008-01-02 Sterix Ltd Compound

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1935554A (en) * 1931-04-24 1933-11-14 Dow Chemical Co Arylides of 2.3-hydroxy-naphthoic acid
US2025116A (en) * 1933-08-22 1935-12-24 Du Pont Arylamide and method for its production
DE838290C (de) * 1950-05-28 1952-05-08 Naphtol Chemie Offenbach Verfahren zur Herstellung von Arylamiden der 2-Oxynaphthalin-1-carbonsaeure
CH330094A (de) * 1954-04-15 1958-05-31 Ciba Geigy Verfahren zum Bedrucken von nicht textilen Flächengebilden
US3064049A (en) * 1959-12-23 1962-11-13 Gen Aniline & Film Corp Tri-hydroxy-naphthanilides
FR1584606A (fr) * 1967-07-31 1969-12-26
US4242260A (en) * 1977-04-27 1980-12-30 Ricoh Company, Ltd. 2-Hydroxy-3-carbonylanilinonaphth-1-yl disazo derivatives and 1-phenyl-3-methyl-5-hydroxypyrazol-4-yl disazo derivatives of 1,4-bis(4-aminostyryl) benzene
US5380879A (en) * 1994-02-18 1995-01-10 Syntex (U.S.A.) Inc. Derivatives of mycophenolic acid
WO1997040028A1 (fr) * 1996-04-23 1997-10-30 Vertex Pharmaceuticals Incorporated Derives d'uree agissant comme inhibiteurs de l'enzyme impdh

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1935554A (en) * 1931-04-24 1933-11-14 Dow Chemical Co Arylides of 2.3-hydroxy-naphthoic acid
US2025116A (en) * 1933-08-22 1935-12-24 Du Pont Arylamide and method for its production
DE838290C (de) * 1950-05-28 1952-05-08 Naphtol Chemie Offenbach Verfahren zur Herstellung von Arylamiden der 2-Oxynaphthalin-1-carbonsaeure
CH330094A (de) * 1954-04-15 1958-05-31 Ciba Geigy Verfahren zum Bedrucken von nicht textilen Flächengebilden
US3064049A (en) * 1959-12-23 1962-11-13 Gen Aniline & Film Corp Tri-hydroxy-naphthanilides
FR1584606A (fr) * 1967-07-31 1969-12-26
US4242260A (en) * 1977-04-27 1980-12-30 Ricoh Company, Ltd. 2-Hydroxy-3-carbonylanilinonaphth-1-yl disazo derivatives and 1-phenyl-3-methyl-5-hydroxypyrazol-4-yl disazo derivatives of 1,4-bis(4-aminostyryl) benzene
US5380879A (en) * 1994-02-18 1995-01-10 Syntex (U.S.A.) Inc. Derivatives of mycophenolic acid
WO1997040028A1 (fr) * 1996-04-23 1997-10-30 Vertex Pharmaceuticals Incorporated Derives d'uree agissant comme inhibiteurs de l'enzyme impdh

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 108, no. 5, 1 February 1988, Columbus, Ohio, US; abstract no. 37339s, KISHIMOTO SATOSHI ET AL.: "Synthesis of anilide derivatives of 1-hydroxy-2-naphthoic acid." page 584; column 2; XP002111113 *
CHEMICAL ABSTRACTS, vol. 110, no. 1, 2 January 1989, Columbus, Ohio, US; abstract no. 3327n, WEBBER D. M. ET AL.: "A quantitative cytochemical assay for osteoclast acid phosphatase activity in fetal rat calvaria." page 309; column 2; XP002111109 *
CHEMICAL ABSTRACTS, vol. 110, no. 24, 12 June 1989, Columbus, Ohio, US; abstract no. 214736h, SEBE ION ET AL.: "Organic pigments -AS-RS naphthol derivatives." page 103; column 1; XP002111114 *
CHEMICAL ABSTRACTS, vol. 110, no. 25, 19 June 1989, Columbus, Ohio, US; abstract no. 228120q, MULLINK H. ET AL.: "Combined immuno- and non-radioactive hybridocytochemistry on cells and tissue sections:" page 317; column 1; XP002111108 *
CHEMICAL ABSTRACTS, vol. 53, no. 12, 25 June 1959, Columbus, Ohio, US; abstract no. 11280a, JUN NISHINO ET AL.: "Azo dyes derived from catechol." page 11280; column 2; XP002111110 *
CHEMICAL ABSTRACTS, vol. 53, no. 15, 10 August 1959, Columbus, Ohio, US; abstract no. 14543f, ERNST HOCHULI ET AL.: "Printing of nontextile sheets." page 14543; column 1; XP002111111 *
CHEMICAL ABSTRACTS, vol. 55, no. 24, 27 November 1961, Columbus, Ohio, US; abstract no. 24333c, C. R. BARR ET AL.: "Indoaniline dyes." page 24333; column 1; XP002111112 *
CHEMICAL ABSTRACTS, vol. 85, no. 17, 25 October 1976, Columbus, Ohio, US; abstract no. 123834n, KEKRE J. S. ET AL.: "Syntheses and biological activity of 1,3-naphthoxazine-2,4-diones." page 636; column 1; XP002111115 *
FRIEDRICH RICHTER: "BEILSTEINS HANDBUCH DER ORGANISCHEN CHEMIE, 4th. Edition, Suppl. II, vol. 13", 1950, SPRINGER VERLAG, BERLIN . GÖTTINGEN . HEIDELBERG (DE), XP002111105 *
HANS-G. BOIT ET AL.: "BEILSTEINS HANDBUCH DER ORGANISCHEN CHEMIE, 4th Edition, Suppl. III, vol. 13", 1973, SPRINGER VERLAG, BERLIN . HEIDELBERG . NEW YORK, XP002111106 *
HISTOCHEM. J., vol. 20, no. 5, 1988, pages 269 - 275 *
INDIAN J. CHEM., SECT. B, vol. 14B, no. 3, 1976, pages 212 - 213 *
J. HISTOCHEM. CYTOCHEM., vol. 37, no. 5, 1989, pages 603 - 609 *
KAGAKU TO KOGYO, vol. 61, no. 3, 1987, pages 84 - 88 *
PATANI G A ET AL: "BIOISOSTERISM: A RATIONAL APPROACH IN DRUG DESIGN", CHEMICAL REVIEWS, vol. 96, no. 8, 1 January 1996 (1996-01-01), pages 3147 - 3176, XP000652176, ISSN: 0009-2665 *
PHOT. SCI. ENG., vol. 5, 1961, pages 195 - 197 *
REINER LUCKENBACH ET AL.: "BEILSIENS HANDBUCH DER ORGANISCHEN CHEMIE, 4th Edition, Suppl. IV, vol. 13", 1985, SPRINGER VERLAG, BERLIN . HEIDELBERG . NEW YORK . TOKYO, XP002111107 *
REV. CHIM. (BUCHAREST), vol. 39, no. 10, 1988, pages 850 - 851 *
YÛKI GÔSEI KAGAKU KYÔKAISHI, vol. 17, 1959, pages 166 - 169 *

Cited By (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7205324B2 (en) 1998-10-29 2007-04-17 Bristol-Myers Squibb Company Inhibitors of IMPDH enzyme
US7053111B2 (en) 1998-10-29 2006-05-30 Bristol-Myers Squibb Co. Inhibitors of IMPDH enzyme
US6399773B1 (en) 1998-10-29 2002-06-04 Bristol-Myers Squibb Co. Compounds derived from an amine nucleus that are inhibitors of IMPDH enzyme
US7060720B2 (en) 1998-10-29 2006-06-13 Bristol-Myers Squibb Co. Inhibitors of IMPDH enzyme
US6420403B1 (en) 1998-10-29 2002-07-16 Edwin J. Iwanowicz Inhibitors of IMPDH enzyme
US6596747B2 (en) 1998-10-29 2003-07-22 Bristol-Myers Squibb Company Compounds derived from an amine nucleus and pharmaceutical compositions comprising same
US6617323B2 (en) 1998-10-29 2003-09-09 Bristol-Myers Squibb Co. Amino-substituted compounds useful as inhibitors of IMPDH enzyme
US6624184B1 (en) 1998-10-29 2003-09-23 Bristol-Myers Squibb Company Amide and diamide inhibitors of IMPDH enzyme for use in treating IMPDH-associated disorders
EP1127054A1 (fr) * 1998-10-29 2001-08-29 Bristol-Myers Squibb Company Nouveaux inhibiteurs de l'enzyme impdh
EP1127054A4 (fr) * 1998-10-29 2006-11-02 Bristol Myers Squibb Co Nouveaux inhibiteurs de l'enzyme impdh
US7989498B2 (en) 1999-04-26 2011-08-02 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6653309B1 (en) 1999-04-26 2003-11-25 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme technical field of the invention
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
US6867299B2 (en) 2000-02-24 2005-03-15 Hoffmann-La Roche Inc. Oxamide IMPDH inhibitors
WO2002022565A1 (fr) * 2000-09-15 2002-03-21 Iconix Pharmaceuticals, Inc. Inhibiteurs de rho c
EP1847263A3 (fr) * 2000-12-18 2009-08-26 Institute of Medicinal Molecular Design, Inc. Inhibiteurs de production et de libération de cytokines inflammatoires
WO2002050045A1 (fr) * 2000-12-18 2002-06-27 Biota Scientific Management Pty Ltd Agents antiviraux
EP1844766A3 (fr) * 2000-12-18 2009-04-29 Institute of Medicinal Molecular Design, Inc. Inhibiteurs de production et de liberation de cytokines inflammatoires
US7579465B2 (en) 2000-12-18 2009-08-25 Biota Scientific Managment Pty. Ltd. Antiviral agents
EP1352650A4 (fr) * 2000-12-18 2005-07-20 Inst Med Molecular Design Inc Inhibiteurs de production et de liberation de cytokines inflammatoires
US8624025B2 (en) 2000-12-18 2014-01-07 Biota Scientific Management Pty Ltd Antiviral agents
EP1352650A1 (fr) * 2000-12-18 2003-10-15 Institute of Medicinal Molecular Design, Inc. Inhibiteurs de production et de liberation de cytokines inflammatoires
EP1847263A2 (fr) * 2000-12-18 2007-10-24 Institute of Medicinal Molecular Design, Inc. Inhibiteurs de production et de libération de cytokines inflammatoires
US8217171B2 (en) 2000-12-18 2012-07-10 Biota Scientific Management Pty. Ltd. Antiviral agents
AU2002221344B2 (en) * 2000-12-18 2006-02-09 Biota Scientific Management Pty Ltd Antiviral agents
AU2002221344C1 (en) * 2000-12-18 2012-02-02 Biota Scientific Management Pty Ltd Antiviral agents
US7829705B2 (en) 2000-12-18 2010-11-09 Biota Scientific Management Pty. Ltd. Antiviral agents
US7951955B2 (en) 2000-12-18 2011-05-31 Biota Scientific Management Pty Ltd Antiviral agents
US7166604B2 (en) 2000-12-18 2007-01-23 Biota Scientific Management Pty Ltd Antiviral agents
JP2004517848A (ja) * 2000-12-18 2004-06-17 バイオウタ サイエンティフィック マネジメント プロプライエタリー リミテッド 抗ウイルス剤
EP1453470A4 (fr) * 2001-11-19 2006-05-17 Iconix Pharm Inc Modulateurs de l'activite de rho c
EP1453470A1 (fr) * 2001-11-19 2004-09-08 Iconix Pharmaceuticals, Inc. Modulateurs de l'activite de rho c
US7148225B2 (en) 2002-03-28 2006-12-12 Neurogen Corporation Substituted biaryl amides as C5A receptor modulators
EP1487796A4 (fr) * 2002-03-28 2005-11-16 Neurogen Corp Biarylamides substitues en tant que modulateurs du recepteur c5a
EP1487796A1 (fr) * 2002-03-28 2004-12-22 Neurogen Corporation Biarylamides substitues en tant que modulateurs du recepteur c5a
US8030517B2 (en) 2002-05-24 2011-10-04 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
US7999109B2 (en) 2002-05-24 2011-08-16 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
US9035096B2 (en) 2002-05-24 2015-05-19 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
JP4660674B2 (ja) * 2002-06-06 2011-03-30 株式会社医薬分子設計研究所 抗アレルギー薬
EA009701B1 (ru) * 2002-06-06 2008-02-28 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. Противоаллергические средства
JPWO2003103665A1 (ja) * 2002-06-06 2005-10-06 株式会社医薬分子設計研究所 抗アレルギー薬
CN1658872B (zh) * 2002-06-06 2010-09-22 株式会社医药分子设计研究所 抗过敏药
WO2003103665A1 (fr) * 2002-06-06 2003-12-18 株式会社医薬分子設計研究所 Anti-allergique
WO2003103655A1 (fr) * 2002-06-10 2003-12-18 株式会社医薬分子設計研究所 Agent therapeutique pour soigner le cancer
CN100506221C (zh) * 2002-06-10 2009-07-01 株式会社医药分子设计研究所 癌症治疗药
AU2003242108B2 (en) * 2002-06-10 2008-09-11 Institute Of Medicinal Molecular Design, Inc. Medicament for treatment of cancer
EA010835B1 (ru) * 2002-06-10 2008-12-30 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. Лекарственное средство для лечения рака
US7547804B2 (en) 2002-07-15 2009-06-16 Myriad Genetics, Inc. Compounds, compositions, and methods employing same
US7227035B2 (en) 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
US8642808B2 (en) 2002-11-18 2014-02-04 Chemocentryx, Inc. Bis-aryl sulfonamides
US7420055B2 (en) 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
US10364240B2 (en) 2002-11-18 2019-07-30 ChemoCentryx. Inc. Aryl sulfonamides
US8211896B2 (en) 2002-11-18 2012-07-03 Chemocentryx, Inc. Aryl sulfonamides
US7582661B2 (en) 2002-11-18 2009-09-01 Chemocentryx, Inc. Aryl sulfonamides
US9890148B2 (en) 2002-11-18 2018-02-13 Chemocentryx, Inc. Aryl sulfonamides
US6939885B2 (en) 2002-11-18 2005-09-06 Chemocentryx Aryl sulfonamides
US7321001B2 (en) 2002-12-20 2008-01-22 Amgen Inc. Asthma and allergic inflammation modulators
US7541383B2 (en) 2002-12-20 2009-06-02 Amgen Inc. Asthma and allergic inflammation modulators
EP2181704A2 (fr) 2002-12-30 2010-05-05 Angiotech International Ag Liberation de medicaments a partir d'une compostion polymere a gelification rapide
WO2004108673A3 (fr) * 2003-06-09 2005-01-27 Boehringer Ingelheim Int Inhibiteurs du papillomavirus
US7582766B2 (en) 2003-06-09 2009-09-01 Boehringer Ingelheim International Gmbh Inhibitors of papilloma virus
WO2004108673A2 (fr) * 2003-06-09 2004-12-16 Boehringer Ingelheim International Gmbh Inhibiteurs du papillomavirus
WO2005021721A3 (fr) * 2003-08-29 2006-05-26 St Jude Childrens Res Hospital Inhibiteurs de la carboxylesterase
WO2005021721A2 (fr) * 2003-08-29 2005-03-10 St. Jude Children's Research Hospital Inhibiteurs de la carboxylesterase
US7973034B2 (en) 2003-08-29 2011-07-05 St. Jude Children's Research Hospital Amide, aryl sulfonamide, aryl urea, and α,β-diketone derived carboxylesterase inhibitors, and their methods of use
WO2005085234A3 (fr) * 2004-03-03 2006-01-26 Syngenta Participations Ag Nouveaux insecticides
US7812170B2 (en) 2004-03-03 2010-10-12 Syngenta Crop Protection, Inc. Insecticides
CN1926129B (zh) * 2004-03-03 2011-06-15 辛根塔参与股份公司 双酰胺杀虫剂
US7166738B2 (en) 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
US7625949B2 (en) 2004-04-23 2009-12-01 Roche Palo Alto Llc Methods for treating retroviral infections
US8329755B2 (en) 2004-04-23 2012-12-11 Roche Palo Alto Llc Methods for treating retroviral infections
WO2006120178A1 (fr) * 2005-05-11 2006-11-16 Novo Nordisk A/S Nouveaux composes d'haloalkylsulfone substitues utiles dans le traitement de l'obesite et de diabetes
WO2006125778A1 (fr) * 2005-05-23 2006-11-30 Novo Nordisk A/S Nouveaux aryl-anilides a substitution trifluoromethoxy
WO2007030617A1 (fr) * 2005-09-09 2007-03-15 Vertex Pharmaceuticals Incorporated Inhibiteurs d'inosine-5'-monophosphate deshydrogenase (impdh) bacterienne
US8202889B2 (en) 2005-09-09 2012-06-19 Vertex Pharmaceuticals Incorporated Inhibitors of bacterial IMPDH
US7388111B2 (en) 2005-10-19 2008-06-17 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
US8168658B2 (en) 2006-02-28 2012-05-01 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase
US7671058B2 (en) 2006-06-21 2010-03-02 Institute Of Medicinal Molecular Design, Inc. N-(3,4-disubstituted phenyl) salicylamide derivatives
US8466180B2 (en) 2006-09-11 2013-06-18 Syngenta Crop Protection Llc Insecticidal compounds
US8263588B2 (en) 2007-04-06 2012-09-11 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
US8481738B2 (en) 2007-04-06 2013-07-09 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
US8507536B2 (en) 2007-04-06 2013-08-13 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
US10941159B2 (en) 2007-04-06 2021-03-09 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
US8084614B2 (en) 2007-04-06 2011-12-27 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
US8952161B2 (en) 2007-04-06 2015-02-10 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
US11713324B2 (en) 2007-04-06 2023-08-01 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
US10336769B2 (en) 2007-04-06 2019-07-02 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
US9422310B2 (en) 2007-04-06 2016-08-23 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
US8183293B2 (en) 2007-12-19 2012-05-22 Amgen Inc. Phenyl acetic acid derivatives
US8653086B2 (en) * 2008-10-21 2014-02-18 Oregon Health & Science University Naphthamides as anticancer agents
US20110301179A1 (en) * 2008-10-21 2011-12-08 Xiangshu Xiao Naphthamides as anticancer agents
EP2411529A4 (fr) * 2009-03-27 2012-09-19 Zacharon Pharmaceuticals Inc Modulateurs de la biosynthèse des glycanes n-liés
EP2411529A2 (fr) * 2009-03-27 2012-02-01 Zacharon Pharmaceuticals, Inc. Modulateurs de la biosynthèse des glycanes n-liés
US11034647B2 (en) 2009-12-10 2021-06-15 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
US10640457B2 (en) 2009-12-10 2020-05-05 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
JP2018027960A (ja) * 2009-12-10 2018-02-22 トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク ヒストンアセチルトランスフェラーゼ活性化剤及びその使用
US9969677B2 (en) 2010-12-22 2018-05-15 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase modulators and uses thereof
US9126944B2 (en) 2013-02-28 2015-09-08 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
US9828345B2 (en) 2013-02-28 2017-11-28 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
US9458110B2 (en) 2013-02-28 2016-10-04 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
US10647661B2 (en) 2017-07-11 2020-05-12 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US11603351B2 (en) 2017-07-11 2023-03-14 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
EP4167999A4 (fr) * 2020-06-19 2024-03-06 Endogena Therapeutics Inc Nouveaux composés et leur utilisation en tant que substances thérapeutiquement actives dans le traitement et/ou la prévention de maladies impliquant l'épithélium pigmentaire rétinien

Also Published As

Publication number Publication date
AU3665199A (en) 1999-11-16
EP1076641A1 (fr) 2001-02-21
JP2002512997A (ja) 2002-05-08

Similar Documents

Publication Publication Date Title
US6653309B1 (en) Inhibitors of IMPDH enzyme technical field of the invention
WO1999055663A1 (fr) Inhibiteurs de l'enzyme impdh
JP4227182B2 (ja) Ｉｍｐｄｈ酵素のインヒビター
US6541496B1 (en) Inhibitors of IMPDH enzyme
US6344465B1 (en) Inhibitors of IMPDH enzyme
US6054472A (en) Inhibitors of IMPDH enzyme
ES2201452T3 (es) Inhibidores de la enzima impdh.
KR100643057B1 (ko) Impdh효소억제제로서의우레아유도체
MXPA98008804A (en) Im enzyme inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 545824

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 09702991

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1999918831

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999918831

Country of ref document: EP